Table 1.

Recent microRNA and mycosis fungoides Studies.

MiRNA type	Year	Biomarker use	Sample	Target/Pathway	Expression	Function	Ref.
miR-93	2021	Progression	Malignant T cells lines	p21	down	Oncogenic molecule	[40]
miR-195–5p	2020	Progression	Skin biopsies and cell lines	ARL2	down	Suppressor gene	[41]
miR-106b	2020	Prognosis	Skin biopsies	P21/TXNIP	up	Oncogenic function	[42]
miR-337	2019	/	Malignant and non-malignant T cell lines	JAK/STAT	up	/	[36]
miR-214	2019	Diagnose	CD4+ T cells	TWIST1/BRD4/miR-214	up	Oncogenic molecule	[31]
miR-155	2018	Diagnose	Malignant T-cell lines (MyLa2059, MyLa3675 and MyLa2000) and HH cells	SATB1/GATA3	up	Oncogenic molecule	[25]
miR-155	2018	Diagnose	HUT102, HUT78 and HH cell lines	JAK/STAT, MAPK/ERK and PI3K/AKT	up	Oncogenic molecule	[16]
miR-155	2017	Diagnose	Peripheral blood	/	up	oncogenic Molecule	[16]
miR-203, R-205	2017	Diagnose	Peripheral blood	/	down	Suppressor gene	[43]
miR-150	2017	Progression	Skin biopsy, HH, HUT78, and MJ cell lines	CCR6	down	Suppressor gene	[43]
miR-214	2017	Prognosis	Skin biopsies	FCRL-3, Tox	up	/	[15]
miR-21	2016	Progression	Skin biopsies	STAT5/JAK3	up	Oncogenic Molecule	[27]
miR-34a	2016	Progression	Skin biopsies	p53	up	oncogenic Molecule	[32]
miR-29a	2016	Progression	Skin biopsies	p53	down	Suppressor gene	[32]
miR-17–92 cluster	2016	Progression	Skin biopsies	/	up	Oncogenic function	[44]
miR-16	2016	Progression	Skin, My-La, MJ, HUT102, HH, and HUT78	miR-16/p21/Bmi1	down	Suppressor gene	[35]
miR-22	2015	/	MyLa2059, MyLa2000, PB2B, MyLa1850 and MySi cell lines	Jak3/STAT3/STAT5	down	Suppressor gene	[13]
miR-223	2014	Progression	Skin biopsies, HH and Hut-78 cell lines	TOX	down	Suppressor gene	[30]
miR-155	2014	Progression	Skin biopsies	STAT4	up	Oncogenic molecule	[21]
miR-155	2013	/	Skin biopsies	STAT5/BIC	up	Oncogenic molecule	[20]
miR-122	2012	Prognosis	Skin, MyLa2000, SeAx and Hut-78 cell lines	p53/Akt	up	Oncogenic molecule	[14]
miR-21	2011	Progression	SeAx cell line	STAT3	up	Oncogenic molecule	[28]